Table 2 Association between baseline characteristics and choice of reduced dose at first prescription in 927,523 NOAC treatments in AIFA Registry (2013–2018).

Sex—Females vs Males

1.25 (1.19–1.31)

1.25 (1.21–1.29)

1.47 (1.42–1.52)

1.82 (1.7–1.95)

 ≥ 65 and < 75 vs < 65 years

1.8 (1.69–1.91)

1.74 (1.63–1.85)

1.57 (1.46–1.7)

2.05 (1.82–2.32)

 ≥ 75 and < 85 vs < 65 years

12.42 (11.32–13.63)

6.29 (5.81–6.82)

7.42 (6.78–8.12)

6.94 (5.91–8.14)

 ≥ 85 vs < 65 years

180.41 (160.24–203.13)

24.82 (22.88–26.93)

38.2 (34.86–41.86)

32.78 (27.88–38.55)

CHA₂DS₂-VASc Score1 vs 0

0.74 (0.63–0.87)

1.22 (0.94–1.59)

0.63 (0.47–0.85)

1.21 (0.75–1.93)

CHA₂DS₂-VASc Score2 vs 0

0.82 (0.69–0.98)

1.73 (1.33–2.26)

0.64 (0.48–0.87)

1.37 (0.85–2.22)

CHA₂DS₂-VASc Score 3 vs 0

0.96 (0.79–1.16)

2.16 (1.64–2.84)

0.72 (0.53–0.98)

1.58 (0.96–2.61)

CHA₂DS₂-VASc Score 4 vs 0

1.07 (0.85–1.33)

2.45 (1.84–3.25)

0.8 (0.58–1.1)

1.71 (1.01–2.89)

CHA₂DS₂-VASc Score 5 vs 0

1.14 (0.89–1.47)

2.56 (1.9–3.45)

0.81 (0.58–1.12)

1.76 (1.01–3.07)

CHA₂DS₂-VASc Score 6 + vs 0

1.34 (0.99–1.82)

2.69 (1.96–3.69)

0.84 (0.59–1.19)

1.84 (1.01–3.37)

HAS-BLED Score1 vs 0

1.28 (1.16–1.4)

1.58 (1.37–1.82)

1.56 (1.3–1.87)

0.87 (0.72–1.07)

HAS-BLED Score 2 vs 0

1.38 (1.25–1.52)

1.77 (1.52–2.05)

1.9 (1.58–2.28)

0.91 (0.74–1.12)

HAS-BLED Score 3 vs 0

1.32 (1.18–1.47)

1.83 (1.57–2.14)

2 (1.66–2.42)

0.84 (0.67–1.05)

HAS-BLED Score 4 + vs 0

1.04 (0.91–1.18)

1.7 (1.44–2.01)

1.91 (1.56–2.33)

0.69 (0.54–0.9)

Diabetes history vs None

0.92 (0.88–0.96)

0.98 (0.95–1.01)

0.95 (0.92–0.99)

0.94 (0.88–1.01)

Hypertension history vs None

0.88 (0.83–0.93)

0.88 (0.84–0.92)

0.74 (0.71–0.78)

0.81 (0.75–0.88)

Stroke/TIA/Thromboembolism history vs None

0.85 (0.78–0.93)

0.89 (0.84–0.95)

0.88 (0.83–0.94)

1 (0.88–1.14)

Vascular disease history vs None

1.29 (1.23–1.35)

1.13 (1.09–1.17)

1.2 (1.16–1.24)

1.13 (1.06–1.22)

CHF history vs None

1.18 (1.12–1.24)

1.35 (1.31–1.4)

1.45 (1.4–1.49)

1.4 (1.31–1.5)

Alcohol use vs None

0.74 (0.7–0.78)

0.69 (0.65–0.72)

0.61 (0.58–0.64)

0.8 (0.73–0.87)

Liver disease vs None

1.57 (1.41–1.74)

1.06 (0.96–1.17)

1.35 (1.23–1.49)

1.48 (1.22–1.78)

Renal disease^a vs None

3.23 (2.98–3.51)

9.86 (9.33–10.41)

6.26 (5.97–6.56)

11.81 (10.66–13.08)

Prior major bleeding or predisposition to bleeding vs None

2.22 (2.12–2.33)

1.53 (1.47–1.59)

1.75 (1.69–1.82)

1.81 (1.68–1.94)

Labile INR vs No

1.17 (1.12–1.22)

1.04 (0.99–1.08)

1.13 (1.08–1.19)

1.1 (1–1.2)

Prior anticoagulant treatment (AVK) vs None

1.01 (0.98–1.04)

0.83 (0.8–0.85)

0.73 (0.7–0.75)

0.8 (0.75–0.85)

Medication usage predisposing to bleeding vs None

2.09 (2.01–2.18)

1.28 (1.24–1.33)

1.14 (1.1–1.19)

1.24 (1.15–1.32)

Prior NOAC treatment (switch) vs None

1.52 (1.42–1.62)

1.6 (1.55–1.66)

1.59 (1.54–1.64)

1.98 (1.88–2.08)